Results 121 to 130 of about 10,874,054 (305)
Special connections: July 17, 1992 [PDF]
, 1992 Time-sensitive news update to monthly University Hospital ...
Office of Publication Services, Boston University Medical Center
core
Molecular Oncology, EarlyView.Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch +13 more
wiley +1 more source
Special connections: September 12, 1991 [PDF]
, 1991 Time-sensitive news update to monthly University Hospital ...
Office of Publication Services, Boston University Medical Center
core
E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer
Molecular Oncology, EarlyView.Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov +3 more
wiley +1 more source
Serving Limited English Proficient Clients [PDF]
, 2014 When serving walk-ins, the goal is to provide the same services, information and referrals as we would provide to the English-speaking public. This is true whether the walk-in ultimately turns out to be eligible for our services or not.
Neighborhood Legal Services, Inc.
core +1 more source
Molecular Oncology, EarlyView.Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau +8 more
wiley +1 more source
Special connections: May 16, 1990 [PDF]
, 1990 Time-sensitive news update to monthly University Hospital ...
Office of Publication Services, Boston University Medical Center
core
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Special connections: June 12, 1990 [PDF]
, 1990 Time-sensitive news update to monthly University Hospital ...
Office of Publication Services, Boston University Medical Center
core